Fonte: Investigational New Drugs. Unidade: FM
Assuntos: REAÇÃO EM CADEIA POR POLIMERASE, ANTINEOPLÁSICOS (APLICAÇÕES TERAPÊUTICAS), PROLIFERAÇÃO CELULAR, FARMACODINÂMICA, ESTADIAMENTO DE NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HAMMOND-THELIN, Lisa A. et al. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies. Investigational New Drugs, v. 30, n. 1, p. 316-326, 2012Tradução . . Disponível em: http://link.springer.com/article/10.1007/s10637-010-9535-y?null. Acesso em: 26 jul. 2024.APA
Hammond-Thelin, L. A., Thomas, M. B., Iwasaki, M., Abbruzzese, J. L., Lassere, Y., Meyers, C. A., et al. (2012). Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies. Investigational New Drugs, 30( 1), 316-326. doi:10.1007/s10637-010-9535-yNLM
Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, Bono J de, Norris J, Matsushita H, Mita A, Rowinsky EK. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies [Internet]. Investigational New Drugs. 2012 ; 30( 1): 316-326.[citado 2024 jul. 26 ] Available from: http://link.springer.com/article/10.1007/s10637-010-9535-y?nullVancouver
Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, Bono J de, Norris J, Matsushita H, Mita A, Rowinsky EK. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies [Internet]. Investigational New Drugs. 2012 ; 30( 1): 316-326.[citado 2024 jul. 26 ] Available from: http://link.springer.com/article/10.1007/s10637-010-9535-y?null
